[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617939":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":36,"centralContacts":39,"locations":47,"responsibleParty":228,"collaborators":11,"id":230,"slug":231,"hasResults":232,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":11,"eligibilityCriteria":236,"healthyVolunteers":232,"sex":237,"minAge":238,"maxAge":11,"enrollmentInfo":239,"targetDuration":11,"studyType":242,"phases":243,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":50,"whyStopped":11,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":260},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,17,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1A: BMS-986525 Monotherapy Dose Escalation","EXPERIMENTAL",null,[13],"Drug: BMS-986525",{"label":15,"type":10,"description":11,"interventionNames":16},"Part 2A: BMS-986525 Monotherapy Dose Expansion",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Part 1B: BMS-986525 Combination with Pumitamig Dose Escalation",[13,20],"Drug: Pumitamig",{"label":22,"type":10,"description":11,"interventionNames":23},"Part 2B: BMS-986525 Combination with Pumitamig Dose Expansion",[13,20],[25,30],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"DRUG","BMS-986525","Specified dose on specified days",[9,18,15,22],{"type":26,"name":31,"description":28,"armGroupLabels":32,"otherNames":33},"Pumitamig",[18,22],[34,35],"BNT-327","BMS-986545",[37],{"name":5,"affiliation":5,"role":38},"STUDY_DIRECTOR",[40,45],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":46,"role":42,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[48,66,80,94,108,122,137,145,161,176,184,200,213],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Karmanos Cancer Institute","RECRUITING","Detroit","Michigan","48201","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-83.04575,42.33143,{"lat":60,"lon":59},[63],{"name":64,"role":42,"phone":65,"phoneExt":11,"email":11},"Hirva Mamdani, Site 0011","313-576-8711",{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":54,"countryCode":55,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Local Institution - 0026","NOT_YET_RECRUITING","Buffalo","New York","14263",{"type":57,"coordinates":73},[74,75],-78.87837,42.88645,{"lat":75,"lon":74},[78],{"name":79,"role":42,"phone":11,"phoneExt":11,"email":11},"Site 0026",{"facility":81,"status":50,"city":82,"state":83,"zip":84,"country":54,"countryCode":55,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Duke Cancer Institute","Durham","North Carolina","27710",{"type":57,"coordinates":86},[87,88],-78.89862,35.99403,{"lat":88,"lon":87},[91],{"name":92,"role":42,"phone":93,"phoneExt":11,"email":11},"Neal Ready, Site 0005","919-681-7460",{"facility":95,"status":50,"city":96,"state":97,"zip":98,"country":54,"countryCode":55,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"University Hospitals Cleveland Medical Center","Cleveland","Ohio","44106",{"type":57,"coordinates":100},[101,102],-81.69541,41.4995,{"lat":102,"lon":101},[105],{"name":106,"role":42,"phone":107,"phoneExt":11,"email":11},"Afshin Dowlati, Site 0004","216-844-5432",{"facility":109,"status":50,"city":110,"state":111,"zip":112,"country":54,"countryCode":55,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":57,"coordinates":114},[115,116],-86.78444,36.16589,{"lat":116,"lon":115},[119],{"name":120,"role":42,"phone":121,"phoneExt":11,"email":11},"Melissa Johnson, Site 0006","615-329-7274",{"facility":123,"status":68,"city":124,"state":125,"zip":126,"country":127,"countryCode":128,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Local Institution - 0029","Beijing","Beijing Municipality","100036","China","CN",{"type":57,"coordinates":130},[131,132],116.39723,39.9075,{"lat":132,"lon":131},[135],{"name":136,"role":42,"phone":11,"phoneExt":11,"email":11},"Site 0029",{"facility":138,"status":68,"city":139,"state":140,"zip":141,"country":127,"countryCode":128,"cosmosGeoPoint":11,"geoPoint":11,"contacts":142},"Local Institution - 0028","Shanghai Shi","Shanghai Municipality","200120",[143],{"name":144,"role":42,"phone":11,"phoneExt":11,"email":11},"Site 0028",{"facility":146,"status":50,"city":147,"state":148,"zip":149,"country":150,"countryCode":151,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Istituto Clinico Humanitas","Rozzano","Milano","20089","Italy","IT",{"type":57,"coordinates":153},[154,155],9.1559,45.38193,{"lat":155,"lon":154},[158],{"name":159,"role":42,"phone":160,"phoneExt":11,"email":11},"Matteo Simonelli, Site 0001","+390282244559",{"facility":162,"status":68,"city":163,"state":164,"zip":165,"country":166,"countryCode":167,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Local Institution - 0020","Hirakata","Osaka","573-1191","Japan","JP",{"type":57,"coordinates":169},[170,171],135.64914,34.81352,{"lat":171,"lon":170},[174],{"name":175,"role":42,"phone":11,"phoneExt":11,"email":11},"Site 0020",{"facility":177,"status":68,"city":178,"state":179,"zip":180,"country":166,"countryCode":167,"cosmosGeoPoint":11,"geoPoint":11,"contacts":181},"Local Institution - 0018","Chuo-ku","Tokyo","104-0045",[182],{"name":183,"role":42,"phone":11,"phoneExt":11,"email":11},"Site 0018",{"facility":185,"status":50,"city":186,"state":187,"zip":188,"country":189,"countryCode":190,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Oncohelp Medical Center","Timișoara","Timiș County","300239","Romania","RO",{"type":57,"coordinates":192},[193,194],21.22571,45.75372,{"lat":194,"lon":193},[197],{"name":198,"role":42,"phone":199,"phoneExt":11,"email":11},"Cristina Oprean, Site 0023","+40745148485",{"facility":201,"status":50,"city":202,"state":11,"zip":203,"country":189,"countryCode":190,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"Centrul de Oncologie Sf. Nectarie SRL","Craiova","200347",{"type":57,"coordinates":205},[206,207],23.8,44.31667,{"lat":207,"lon":206},[210],{"name":211,"role":42,"phone":212,"phoneExt":11,"email":11},"Michael Schenker, Site 0003","40727774974",{"facility":214,"status":50,"city":215,"state":11,"zip":216,"country":217,"countryCode":218,"cosmosGeoPoint":219,"geoPoint":223,"contacts":224},"Hospital Universitario 12 de Octubre","Madrid","28041","Spain","ES",{"type":57,"coordinates":220},[221,222],-3.70256,40.4165,{"lat":222,"lon":221},[225],{"name":226,"role":42,"phone":227,"phoneExt":11,"email":11},"Luis Paz-Ares Rodriguez, Site 0009","0034913908922",{"type":229,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100617939","phase-1-a-study-to-assess-the-safety-and-tolerability-of-bms-986525-alone-and-in-combination-therapy-in-participants-with-relapsedrefractory-small-cell-lung-cancer-100617939",false,"NCT07325136","A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed\u002FRefractory Small Cell Lung Cancer","A Phase 1\u002F2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed\u002FRefractory Small Cell Lung Cancer","Inclusion Criteria\n\n* Participants must have histologically or cytologically documented relapsed\u002Frefractory small cell lung cancer (R\u002FR-SCLC).\n* Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.\n* In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.\n\nExclusion Criteria\n\n* Participants must not have any untreated CNS metastases.\n* Participants must not have an active, known or suspected autoimmune disease.\n* Participants must not have had a prior organ or tissue allograft.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":240,"type":241},240,"ESTIMATED","INTERVENTIONAL",[244,245],"PHASE1","PHASE2","The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed\u002FRefractory Small Cell Lung Cancer",[248],"Relapsed\u002FRefractory Small Cell Lung Cancer",[250],"Extensive stage-small cell lung cancer (ES-SCLC)","2026-08-17",{"date":253,"type":254},"2026-08-18","ACTUAL",{"date":256,"type":254},"2026-02-03",{"date":258,"type":241},"2029-04-24",{"name":5,"class":6},13]